Uxin shares drop 45% as predicted by InvestingPro’s Fair Value model
Disc Medicine Inc’s stock reached a significant milestone, hitting a 52-week high of 96.09 USD, slightly above the previous high of 95.95 USD. This marks a notable achievement for the company, reflecting a positive trend in its stock performance over the past year. With a substantial 95.48% price increase over the last six months and a beta of 2.53, the stock has shown remarkable momentum despite its high volatility. Investors have witnessed a 42.55% increase in the stock’s value over the last 12 months, underscoring the market’s growing confidence in the company’s prospects. The surge to this 52-week high highlights Disc Medicine’s strong position in the market and suggests continued investor optimism. However, InvestingPro analysis indicates the stock may be trading above its Fair Value, with analyst price targets ranging from 91 USD to 153 USD. Discover more insights and 14 exclusive ProTips in Disc Medicine’s comprehensive Pro Research Report, available to subscribers.
In other recent news, Disc Medicine has announced the pricing of an upsized public offering valued at approximately $250 million. The company is selling 2,619,049 shares of common stock and pre-funded warrants to purchase 59,523 shares at $84.00 per share and $83.9999 per warrant, respectively. Additionally, a selling stockholder, AI DMI LLC, is offering 297,619 shares. Disc Medicine also launched a $220 million stock offering aimed at supporting the potential commercialization of bitopertin and funding research and clinical development. Jefferies has maintained a Buy rating on Disc Medicine, highlighting the company’s strong performance and anticipated momentum through key catalysts expected by late 2025 and early 2026. Raymond James reiterated its Strong Buy rating, citing the potential of DISC-0974 as a future growth driver. The company plans to present initial data from its RALLY-MF Phase 2 trial of DISC-0974 at the American Society of Hematology Annual Meeting in December 2025. The trial evaluates DISC-0974 for anemia in myelofibrosis patients, both as a monotherapy and in combination with JAK inhibitors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.